265 related articles for article (PubMed ID: 15136627)
21. Simple quantification of skeletal muscle glucose utilization by static 18F-FDG PET.
Yokoyama I; Inoue Y; Moritan T; Ohtomo K; Nagai R
J Nucl Med; 2003 Oct; 44(10):1592-8. PubMed ID: 14530472
[TBL] [Abstract][Full Text] [Related]
22. Influence of N-butylscopolamine on SUV in FDG PET of the bowel.
Sanghera B; Emmott J; Wellsted D; Chambers J; Wong WL
Ann Nucl Med; 2009 Jul; 23(5):471-8. PubMed ID: 19444552
[TBL] [Abstract][Full Text] [Related]
23. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
[TBL] [Abstract][Full Text] [Related]
24. Correlation of PET/CT standardized uptake value measurements between dedicated workstations and a PACS-integrated workstation system.
Meirelles GS; Kijewski P; Akhurst T
J Digit Imaging; 2007 Sep; 20(3):307-13. PubMed ID: 16972011
[TBL] [Abstract][Full Text] [Related]
25. Revisiting Weight-Normalized SUV and Lean-Body-Mass-Normalized SUV in PET Studies.
Sarikaya I; Albatineh AN; Sarikaya A
J Nucl Med Technol; 2020 Jun; 48(2):163-167. PubMed ID: 31604893
[TBL] [Abstract][Full Text] [Related]
26. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans.
Freedman NM; Sundaram SK; Kurdziel K; Carrasquillo JA; Whatley M; Carson JM; Sellers D; Libutti SK; Yang JC; Bacharach SL
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):46-53. PubMed ID: 12483409
[TBL] [Abstract][Full Text] [Related]
27. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction.
Kim CK; Gupta NC
Nucl Med Commun; 1996 Oct; 17(10):890-4. PubMed ID: 8951911
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the normal adrenal gland with 18F-FDG PET/CT.
Bagheri B; Maurer AH; Cone L; Doss M; Adler L
J Nucl Med; 2004 Aug; 45(8):1340-3. PubMed ID: 15299059
[TBL] [Abstract][Full Text] [Related]
29. Using SUV as a guide to 18F-FDG dose reduction.
Cheng DW; Ersahin D; Staib LH; Della Latta D; Giorgetti A; d'Errico F
J Nucl Med; 2014 Dec; 55(12):1998-2002. PubMed ID: 25453048
[TBL] [Abstract][Full Text] [Related]
30. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
31. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.
Miyauchi T; Wahl RL
Eur J Nucl Med; 1996 May; 23(5):517-23. PubMed ID: 8698055
[TBL] [Abstract][Full Text] [Related]
32. The appropriate whole-body index on which to base standardized uptake value in 2-deoxy-2-[(18)F]fludeoxyglucose PET.
Keramida G; Hunter J; Dizdarevic S; Peters AM
Br J Radiol; 2015 Aug; 88(1052):20140520. PubMed ID: 26081445
[TBL] [Abstract][Full Text] [Related]
33. Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT.
Abikhzer G; Alabed YZ; Azoulay L; Assayag J; Rush C
AJR Am J Roentgenol; 2011 Jan; 196(1):176-80. PubMed ID: 21178064
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
Schöder H; Erdi YE; Chao K; Gonen M; Larson SM; Yeung HW
J Nucl Med; 2004 Apr; 45(4):559-66. PubMed ID: 15073250
[TBL] [Abstract][Full Text] [Related]
35. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
36. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
Inglese E; Leva L; Matheoud R; Sacchetti G; Secco C; Gandolfo P; Brambilla M; Sambuceti G
J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
[TBL] [Abstract][Full Text] [Related]
37. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
Zhuang H; Pourdehnad M; Lambright ES; Yamamoto AJ; Lanuti M; Li P; Mozley PD; Rossman MD; Albelda SM; Alavi A
J Nucl Med; 2001 Sep; 42(9):1412-7. PubMed ID: 11535734
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of CT-based lean-body SUV.
Hamill JJ; Sunderland JJ; LeBlanc AK; Kojima CJ; Wall J; Martin EB
Med Phys; 2013 Sep; 40(9):092504. PubMed ID: 24007180
[TBL] [Abstract][Full Text] [Related]
39. Influence of Statistical Fluctuation on Reproducibility and Accuracy of SUVmax and SUVpeak: A Phantom Study.
Akamatsu G; Ikari Y; Nishida H; Nishio T; Ohnishi A; Maebatake A; Sasaki M; Senda M
J Nucl Med Technol; 2015 Sep; 43(3):222-6. PubMed ID: 26271802
[TBL] [Abstract][Full Text] [Related]
40. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
Hong R; Halama J; Bova D; Sethi A; Emami B
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):720-6. PubMed ID: 17293230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
